Skip to main content

Genentech Expands ZFP License with Sangamo

NEW YORK (GenomeWeb News) – Sangamo BioSciences has expanded a research and license agreement with Genentech to focus its zinc finger technology on additional targets for production cell lines.
 
Sangamo’s technology uses naturally occurring transcription factors, called ZFPs, that bind to DNA to regulate gene expression.
 
Sangamo said the ZFPs engineer ZFNs, which contain a nuclease component that can induce modification of a target gene of interest. Company CEO Edward Lanphier said the firm’s technology offers a “highly specific method to efficiently alter genes in eukaryotic cells.”
 
Sangamo had a previous agreement with Genentech to design and engineer additional ZFNs that target genes that Genentech is interested in using to improve pharmaceutical production in mammalian cells.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.